CyclinD1 and p57kip2 as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma

Yi Ru1,*, Xiao-Jie Chen2,*, Zhi-Wei Zhao1, Peng-Fei Zhang1, Shuai-Hao Feng1, Qiang Gao1, She-Gan Gao1,2,3,4 and Xiao-Shan Feng1,3,4

1The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003, China
2Medical College, Henan University of Science and Technology, Luoyang, Henan 471003, China
3Henan Key Laboratory of Cancer Epigenetics, Henan University of Science and Technology, Luoyang, Henan 471003, China
4Cancer Institute, Henan University of Science and Technology, Luoyang, Henan 471003, China

*These authors contributed equally to this work and co-first authors

Correspondence to: Xiao-Shan Feng, email: fengxiaoshan880923@163.com

Keywords: gastric cardia adenocarcinoma, p57kip2, cyclinD1, clinical stage, different degrees of differentiation

ABSTRACT

Objective: This study aims to investigate the expression and significance of p57kip2 and cyclinD1 in gastric cardia adenocarcinoma (GCA). p57kip2 is a negative regulator in the cell cycle. On the contrary, cyclinD1 is a positive regulator of cell cycle progression. Methods: Thirty-two cases of GCA tissues and adjacent non-cancerous tissues were collected for this study. Immunohistochemistry and fluorescence qualitative PCR was used to determine the level of p57kip2 and cyclinD1 in GCA and its adjacent non-cancerous tissues. Furthermore, the correlation between the mRNA/protein and GCA clinical pathologic parameters were analyzed, and the relationship of p57kip2 and cyclinD1 in GCA were also evaluated. Results: The expression of p57kip2 significantly lower in GCA (P = 0.036), and there was a significant correlation in the different degrees of differentiation (P < 0.05). Furthermore, median survival time was 41 months for patients with high mRNA expression of p57kip2. This was longer compared to patients with low mRNA expression of P57kip2 (37 months, X² = 4.788, P = 0.029). The expression of cyclinD1 was significantly higher in GCA (P = 0.002), and was significant correlated to clinical stage (P<0.05). Median survival time was 34 months in patients with high mRNA expression of cyclinD1, which was shorter than in patients with low expression of cyclinD1 mRNA (41 months, X² = 4.071, P = 0.044). The protein expression of p57kip2 was not correlated to the protein expression of cyclinD1 (P = 0.55). Conclusion: The expression of p57kip2 and cyclinD1 are likely to suppress or promote the tumorigenesis and progression of GCA.

INTRODUCTION

In many parts of northern China, gastric cardia adenocarcinoma (GCA) is a common cancer disease [1]. In recent years, studies have continuously revealed that GCA is a malignancy that differs from esophageal malignancy [2]. Furthermore, the regional distribution of GCA is different from gastric and esophageal cancer [3]. Hence, these should be studied as an independent disease. Tumors can be caused by cells that have unlimited autonomous division and proliferation. Normal cell division, proliferation, differentiation and aging maintain the stability of the body. Disorder in cell cycle progression can lead to a chaotic process. The regulation of different checkpoints in cell cycle progression is recognized as the cell cycle regulation mode. The most important checkpoints of the cell cycle are G1/S and G2/M, as well as the junction of the mitotic metaphase/anaphase. An
uncontrollable checkpoint would lead to the manifestation of a tumor, and almost all functions of oncogenes and cancer suppressor genes are correlated to cell cycle. As a member of the cyclin-dependent kinases inhibitors (CDKI) and a negative regulatory factor in cell cycle, p57kip2 may interfere with cell cycle progression via blocking the progression in the G1 phase, exerting an anti-tumor effect [4]. Instead, as a positive regulator of cell cycle progression, cyclinD1 overexpression may accelerate G1/S progression, accelerating cell proliferation [5].

In our study, real-time fluorescence qualitative polymerase chain reaction (PCR), immunohistochemical and western blot assays were employed to detect the expression of p57kip2 and cyclinD1 in GCA tissues and its adjacent non-cancerous tissues. The study aimed to investigate the status and significance of p57kip2 and cyclinD1 in the occurrence and development of GCA, and explore the potential mechanisms of the inhibitory effect of p57kip2 on GCA. Our findings may provide markers for the diagnosis, treatment and prognosis of GCA; which would be beneficial for developing strategies to improve the diagnosis, treatment and prognosis of GCA.

**RESULTS**

**mRNA expression of p57kip2 and cyclinD1 in GCA and its adjacent non-cancerous tissues**

At mRNA level, the relative expression of p57kip2 was 6.985 ± 1.138 and 6.592 ± 1.244 in GCA and its adjacent non-cancerous tissues, respectively; while the relative expression of cyclinD1 was 6.389 ± 1.154 and 6.980 ± 1.286 in GCA and its adjacent non-cancerous tissues, respectively. Significant differences in the expression of p57kip2 and cyclinD1 were observed between the two groups (P < 0.01 or 0.05, Figure 1).

**Protein expression of p57kip2 and cyclinD1 in GCA and its adjacent non-cancerous tissues**

At protein level (immunohistochemistry), 6 and 26 patients were positive for p57kip2 in GCA and its adjacent non-cancerous tissues, respectively; while 27 and 5 patients were positive for cyclinD1 in GCA and its adjacent non-cancerous tissues, respectively. Significant differences in p57kip2 and cyclinD1 expression were observed between the two groups (P < 0.05 or 0.01, Figure 2).

At protein level (western blot), the relative expression of p57kip2 was 0.414 ± 0.170 and 0.601 ± 0.218 in GCA and its adjacent non-cancerous tissues, respectively; while the relative expression of cyclinD1 was 0.587 ± 0.112 and 0.386 ± 0.109 in GCA and its adjacent non-cancerous tissues, respectively. Significant differences in the expression of p57kip2 and cyclinD1 were observed between the two groups (P < 0.05 or 0.01, Figure 3).

**The correlation of p57kip2 and cyclinD1 mRNA expression with the clinicopathological features of GCA**

Based on the expression levels of p57kip2 mRNA obtained by qRT–PCR, we divided the 32 GCA patients into a high- p57kip2 expression group (n = 18) and a low-p57kip2 expression group (n = 14) according to the median expression of tumor tissue (6.514). In the same way, we divided patients into a high- cyclinD1 expression group (n = 21) and a low- cyclinD1 expression group (n = 11) according to the median expression of tumor tissue (7.022). Then we analyzed the correlation of p57kip2 and cyclinD1 expression levels with the clinicopathological characteristics of patients with GCA (Table 1). Significant differences were observed in p57kip2 mRNA expression among patients with different degrees of differentiation, and cyclinD1 among patients with different clinical stages (P < 0.01 or 0.05). In addition, patients with lymph node metastasis had different mRNA expression levels of cyclinD1, compared with patients without lymph node metastasis. Moreover, there were no differences in p57kip2 and cyclinD1 mRNA expression between male and female patients, among patients with or without stomach diseases, among patients with or without a family history of cancer, and among patients in different age groups (P > 0.05, Table 1).

**The correlation of p57kip2 and cyclinD1 protein expression with the clinicopathological features of GCA**

Significant differences were observed in the protein expression of p57kip2 among patients with different degrees of differentiation, and in the protein expression of cyclinD1 among patients with different clinical stages (P < 0.01 or 0.05). There were no differences in the protein expression of p57kip2 and cyclinD1 between genders, among patients with or without stomach diseases, among patients with or without a family history of cancer, and among patients in different age groups (P > 0.05, Table 2).

**The correlation between p57kip2 and cyclinD1 protein expression in GCA**

On the basis of the median expression of p57kip2 and cyclinD1 in GCA, patients were divided into four groups; and the relation between the expression of p57kip2 and cyclinD1 protein was assessed. We found that p57kip2 protein expression was not correlated to cyclinD1 protein expression (r = −0.202, P = 0.55, Table 3).

**Correlation of the mRNA expression of p57kip2 and cyclinD1 with the prognosis of GCA**

Median survival time was 41 months in GCA patients with high mRNA expression of p57kip2, which was longer
than in patients with low mRNA expression of p57kip2 (37 months, $X^2 = 4.788, P = 0.029$; Figure 1C). Furthermore, median survival time was 34 months in patients with high mRNA expression of cyclinD1, which was shorter than in patients with low mRNA expression of cyclinD1 (41 months, $X^2 = 4.071, P = 0.044$; Figure 1D). A univariate Cox analysis showed that the stomach diseases, lymph node metastasis, TNM stage, CyclinD1 and p57Kip2 expression were correlated with the survival (Table 4). Multivariate analysis using the Cox proportional hazard model demonstrated that CyclinD1 and p57Kip2 expression was an independent risk factors for OS ($P = 0.027, P = 0.008$, Table 4) in addition to TNM stage ($P = 0.000$, Table 4). These results identified that overexpression of CyclinD1 or lower expression of p57Kip2 seemed to be a predictive factor of poor survival of GCA, suggesting that they may contribute to GCA pathogenesis and can be employed as powerful independent prognostic factors.

**DISCUSSION**

Cancer is an outcome of the cooperation and interaction of multi-factors, and its progression involves multiple genes and multiple steps. This is true for GCA. Recurrence and metastasis are major problematic issues that threaten human health. More investigators continue to propose that conjoint multi-markers analysis would be superior to one marker in predicting the cancers prognosis. With the development of biotechnology, increasing genes that may promote or inhibit cancer development have been identified. Therefore, exploring the correlation between genes that play a role in inhibiting or promoting cancer development is important for predicting the prognosis and treatment efficacy of cancers in clinic.

P57kip2 is a tumor metastasis suppressor. The deficiency or downregulation of P57kip2 expression have been observed in multiple cancers including lymphomas.

![Figure 1](image_url)

**Figure 1**: (A) Quantitative Real Time PCR(qRT-PCR) of P57/Kip2 mRNA in GCA and the adjacent non-cancerous tissues. (B) Quantitative Real Time PCR(qRT-PCR) of cyclinD1 mRNA in GCA and the adjacent non-cancerous tissues. (C) Correlation between P57kip2 mRNA expression and survival time. (D) Correlation between cyclinD1 mRNA expression and survival time.
Figure 2: (A) Positive expression of P57/Kip2 in the adjacent non-cancerous tissues (×20). (B) Positive expression of P57/Kip2 in the adjacent non-cancerous tissues (×40). (C) Negative expression of P57/Kip2 in GCA (×20). (D) Negative expression of P57/Kip2 in GCA (×40). (E) Negative expression of CyclinD1 in the adjacent non-cancerous tissues (×20). (F) Negative expression of CyclinD1 in the adjacent non-cancerous tissues (×40). (G) Positive expression of CyclinD1 in GCA (×20). (H) Positive expression of CyclinD1 in GCA (×40).
In most tumors, the main means that lead p57kip2 to inactivate were reported as modifications after transcription and translation. The lack and loss of heterozygosity, DNA methylation and histone acetylation, microRNAs, many signal transduction pathways and phosphorylation, and ubiquitination in the regulation of p57kip2 expression promote the malignant biological behavior of cancer cells [13–17]. The inhibitory activity of cyclin/CDK depends on the amino terminal domain and the nuclear localization signal (NLS) at the carboxy terminal, they were CDK binding/inhibitory region. In contrast, CIP/KIP proteins exhibit divergent carboxy terminal domains. Human p57kip2 and p21CIP1 has a proliferating cell nuclear antigen (PCNA) binding domain required for inhibiting DNA replication [18]. What's more, extracellular factors such as TGF-β, IGF-1 and pituitary adenylate cyclase-activating peptide [19–21], and transcription factors such as CTIP2 and HES1 [22, 23], which are known to play important roles during corticogenesis, regulate the positive or negative expression of p57kip2. Shin revealed that p57 serves as a tumor suppressor in GCA [8]. However, the functional role of p57 in GCA remains unclear. Our results determined that p57kip2 can serve as a tumor suppressor in GCA. Furthermore, our results revealed that the mRNA and protein expression of p57kip2 were consistent. The p57kip2 expression in GCA was markedly lower than in adjacent non-cancerous tissues. In addition, p57kip2 expression was different in patients with different degrees of differentiation. That is, the expression of p57kip2 in patients with poorly differentiated GCA was significantly lower than in patients with well-differentiated GCA. These findings suggest that the more invasive capabilities are, the lower the p57kip2 expression becomes. However, there was no marked difference in p57kip2 expression between genders, patients in different age groups and in different clinical stages. Furthermore, there was no marked difference among patients with or without stomach diseases, and patients with or without a family history of cancer. The survival curve analysis revealed that patients with high mRNA expression of p57kip2 had a median survival time of 41 months, which was longer than in patients (34 months) with high mRNA expression of p57kip2. (χ² = 4.788, P = 0.029).

The cyclinD1 gene is located in 11q13 and possesses five exons and four introns. Its length is approximately 15 kb, and encodes 295 amino acids.
with a molecular weight of 34 kD. CyclinD1 expression undergoes periodic alteration with the progression of the cell cycle under physiological conditions. Generally, cyclinD1 is synthesized in the G0 phase. Its complex reaches a maximal level in the G1 phase and is reduced in the S phase. CyclinD1 expression remains at a low level in other phases of the cell cycle. Furthermore, cyclinD1 can promote the progression of the cell cycle and regulate cell proliferation. Evidence has shown that cyclinD1 acts in a retinoblastoma (Rb)-dependent manner [24]. The over-expression of cyclinD1 may cause the transition across the G1/S checkpoint, influence the normal regulation of the cell cycle, and result in rapid cell proliferation; which finally causes the formation of cancers. There are three members in cyclinD family: cyclinD1, cyclinD2 and cyclinD3. The overexpression of cyclinD1 can be detected in breast cancer [25], as well as in head and neck carcinoma [24]. It is attributed to the promotion of cell cycle progression of cyclinD1. CyclinD1 expression is very low in normal breast tissues. In breast cancer, the mRNA of cyclinD1 is 25-81% and protein expression is 45-83%, respectively [26, 27]. Umekita et al. [28] followed-up 173 patients with breast cancer after surgery, and their results revealed that the expression of cyclinD1 was at a high level in most patients, and that this could be used as an independent factor for indicating the prognosis of ER negative breast expression. In breast cancer, Wang et al. [29] investigated the expression of cyclinD1 in the metastasis and migration of breast cancer. The study revealed that the expression of cyclinD1 was correlated to the metastasis of breast cancer, and breast cancer with high cyclinD1 expression had a poor prognosis. The results suggest that cyclinD1 may facilitate the migration of cancer cells and promote their growth. Furthermore, cyclinD1 could effect on cell proliferation not only at the cellular level, but also in vivo (such as the ESCC animal model [30]). In ESCC, the increased expression of cyclinD1 was related to a poor prognosis [31]. Cattani et al. [32] found that in laryngeal cancer, cyclinD1 expression was associated with HPV infection. CyclinD1 expression was at a high level in patients with HPVE6/7 infection, and interfered with the cell cycle; resulting in the occurrence of laryngeal cancer. Our results revealed that the mRNA and protein expression of cyclinD1 were consistent in GCA. The expression of cyclinD1 In GCA

| Clinicopathological features | Relative expression of CyclinD1 | P | Relative expression of p57/Kip2(%) | P |
|-----------------------------|-------------------------------|---|----------------------------------|---|
| Age (year)                  |                               |   |                                  |   |
| < 60                        | 6.825 ± 1.121                 | 0.320 | 6.456 ± 1.031                 | 0.586 |
| ≥ 60                        | 6.995 ± 1.157                 |   | 6.359 ± 1.157                 |   |
| Male/female                 |                               |   |                                  |   |
| Male                        | 7.121 ± 1.058                 | 0.218 | 6.268 ± 1.227                 | 0.353 |
| Female                      | 6.877 ± 1.203                 |   | 6.448 ± 1.090                 |   |
| The stomach diseases        |                               |   |                                  |   |
| No                          | 6.827 ± 1.214                 | 0.307 | 6.516 ± 1.012                 | 0.310 |
| Yes                         | 6.993 ± 1.124                 |   | 6.209 ± 1.272                 |   |
| Family history of cancer    |                               |   |                                  |   |
| No                          | 6.895 ± 1.212                 | 0.445 | 6.451 ± 1.147                 | 0.162 |
| Yes                         | 6.996 ± 1.130                 |   | 6.173 ± 1.248                 |   |
| Pathological grade          |                               |   |                                  |   |
| differentiated              |                               | 0.312 |                                 | 0.032 |
| Middle-low differentiated    | 6.988 ± 1.133                 |   | 6.083 ± 1.215                 |   |
| High-middle differentiated   | 6.810 ± 1.209                 |   | 6.513 ± 1.012                 |   |
| Clinical stage              |                               |   |                                  |   |
| < III b                     | 6.620 ± 1.214                 | 0.021 | 6.408 ± 0.127                 | 0.697 |
| ≥ III b                     | 7.283 ± 1.131                 |   | 6.363 ± 0.138                 |   |
| Lymph node metastasis       |                               |   |                                  |   |
| Negative                    | 6.493 ± 1.169                 | 0.042 | 6.521 ± 1.009                 | 0.068 |
| Positive                    | 6.876 ± 1.140                 |   | 6.091 ± 1.185                 |   |

Table 1: Correlation of mRNA expressions of p57<sup>kip2</sup> and CyclinD1 with clinicopathological features of GCA
was markedly higher than in its adjacent non-cancerous tissues. In addition, cyclinD1 expression was different in patients with different clinical stages and in patients with and without metastasis. That is, the expression of cyclinD1 in patients with clinical stage IIIb-IV GCA was significantly higher than in patients with clinical stage I- IIIa GCA. These findings suggest that the higher the cyclinD1 expression, the more potent the metastatic and invasive capability of cancer cell in GCA is. However, there is no marked difference in cyclinD1 expression between genders, among patients in different age groups, and between patients with and without gastric diseases. Survival curve analysis revealed that patients with low cyclinD1 mRNA expression had a median survival time of 41 months, which was longer than in patients (34 months) with high cyclinD1 mRNA expression ($X^2 = 4.071, P = 0.044$).

### MATERIALS AND METHODS

#### Sample collection

Between January 2012 and March 2014, 32 patients with GCA were recruited from the Department of Thoracic Surgery in the First Affiliated Hospital of Henan University of Science and Technology. These patients received operative treatment, and GCA was pathologically confirmed. All patients did not receive radiotherapy and chemotherapy before surgery, and had complete clinical, pathological and follow-up data. Among these patients,

### Table 2: Correlation of protein expressions of p57$^{Kip2}$ and CyclinD1 with clinicopathological features of GCA

| Clinicopathological features | CyclinD1 positive (%) | CyclinD1 negative (%) | p | p57$^{Kip2}$ positive (%) | p57$^{Kip2}$ negative (%) | p |
|-----------------------------|-----------------------|-----------------------|---|----------------------------|---------------------------|---|
| Age (year)                  |                       |                       |   |                            |                           |   |
| < 60                        | 2(40.0)               | 9(33.3)               | 0.773 | 10(38.5)                  | 1(16.7)                   | 0.637 |
| ≥ 60                        | 3(60.0)               | 18(66.7)              |   |                           |                           |   |
| Male/female                 |                       |                       |   |                            |                           |   |
| Male                        | 4(80.0)               | 26(96.3)              | 0.292 | 25(96.2)                  | 5(83.3)                   | 0.345 |
| Female                      | 1(20.0)               | 1(3.7)                |   |                           |                           |   |
| The stomach diseases        |                       |                       |   |                            |                           |   |
| No                          | 4(80.0)               | 8(29.6)               | 0.053 | 11(42.3)                  | 1(16.7)                   | 0.370 |
| Yes                         | 1(20.0)               | 19(70.4)              |   |                           |                           |   |
| Family history of cancer    |                       |                       |   |                            |                           |   |
| No                          | 3(60.0)               | 16(44.4)              | 0.645 | 14(53.8)                  | 5(83.3)                   | 0.185 |
| Yes                         | 2(40.0)               | 11(55.6)              |   |                           |                           |   |
| Pathological grade differentiated |                   |                       | 1.000 |                             |                           |   |
| Middle-low differentiated    | 1(20.0)               | 6(22.2)               |   |                           |                           |   |
| High-middle differentiated   | 4(80.0)               | 21(77.8)              |   |                           |                           |   |
| Clinical stage              |                       |                       |   |                            |                           |   |
| < IIIb                      | 5(100)                | 10(37.0)              | 0.015 | 10(38.5)                  | 1(16.7)                   | 0.637 |
| ≥ IIIb                      | 0(0)                  | 17(63.0)              |   |                           |                           |   |
| Lymph node metastasis       |                       |                       |   |                            |                           |   |
| Negative                    | 2(40.0)               | 6(22.2)               | 0.578 | 8(30.8)                   | 0(0)                      | 0.117 |
| Positive                    | 3(60.0)               | 21(80.0)              |   |                           |                           |   |

### Table 3: Correlation between p57/Kip protein expression and CyclinD1 protein expression in GCA

| p57$^{Kip2}$ | CyclinD1 |
|----------------|-----------|
| +             | +         | 6         |
| +             | −         | 0         |
| −             | +         | 21        |
| −             | −         | 5         |

$P = 0.55$. 

(34 months) with high cyclinD1 mRNA expression ($X^2 = 4.071, P = 0.044$).
30 patients were male and two patients were female; and the median age of these patients was 61.4 years (range: 39-76 years). GCA was classified as highly or moderately differentiated GCA (n = 25), and middle-low differentiated GCA (n = 7). Clinical pathologic staging was performed according to the TNM staging system formulated by the Union for International Cancer Control (UICC, 1997). Clinical staging was performed as a stage < IIIB GCA (n = 15) and as stage ≥ IIIB (n = 17). Additionally, 24 patients were diagnosed with lymph node metastasis, and eight patients had no lymph node metastasis. The follow up period ranged between 1–48 months. The GCA and its adjacent non-cancerous tissues were collected, divided into two groups, and stored in liquid nitrogen.

**Materials and reagent**

Total RNA isolation kit (Shanghai Tiangen Biotech Co., Ltd.), qPCR Master Mix (Vazyme Biotech Co., Ltd.), reverse transcription kit (Vazyme Biotech Co., Ltd.), antibodies against p57kip2 and cyclinD1 (Abcam Biotech Co., Ltd., UK) and primers (Table 5, Shanghai Sangon) were used in this study.

**Detection of p57kip2 and cyclinD1 mRNA expression (qPCR)**

Total RNA was extracted by TRIZOL Regent kit. UV spectrophotometer was used to determine the concentration of RNA. The first strand of RNA was synthesized with reverse transcription. Fluorescence qualitative PCR was performed in 20-μl mixture (Amplification primers are shown in Table 5), and the conditions as follows: denaturation at 95°C for five minutes, 95°C for 10 seconds, annealing at 60°C (58°C for β-actin, 56°C for p57kip2 and cyclinD1), and extension at 72°C for 20 seconds for 40 cycles. Three wells were used for each group. The 2^(-ΔΔCT) method was used to calculate the expression of p57kip2 and cyclinD1.

**The detection of p57kip2 and cyclinD1 protein expression**

Western blot Tissues were kept in liquid nitrogen and total protein was extracted with RIPA lysis buffer. The BCA method was used to determine the protein concentration. The protein solution was mixed with a loading buffer, and boiled for use. Then, 50 µg of total protein were loaded for electrophoresis at 20 mA for three hours, and transfer membrane was performed at a constant current for two hours. Next, the membrane was blocked with 5% non-fat milk at room temperature for one hour, and treated with the primary antibody at a ratio of 1:1,000, overnight at 4°C. After washing three times with TBST (for 10 minutes each), the membrane was treated with HRP conjugated secondary antibody at a ratio of 1:3,000 for two hours at room temperature. Then, the membrane was washed three times with TBST (for 10 minutes each), and visualization was performed using an ECL kit. β-actin was used as an internal control.

**Table 4: Univariate and multivariate analysis of different prognostic factors for OS in 32 patients with GCA**

| Prognostic factors                     | Univariate analysis | Multivariate analysis |
|---------------------------------------|---------------------|-----------------------|
|                                       | HR                  | 95% CI                | P value | HR                  | 95% CI                | P value |
| Age (> 60/≤ 60)                        | 0.662               | 0.313–1.126           | 0.253   |                     |                      |         |
| Gender (Male/Female)                   | 1.122               | 0.614–2.179           | 0.799   |                     |                      |         |
| The stomach diseases (NO/YES)         | 1.822               | 1.135–3.026           | 0.039*  |                     |                      |         |
| Family history of cancer (NO/YES)     | 0.821               | 0.603–1.192           | 0.281   |                     |                      |         |
| Differentiation (Poor/Well+Moderate)   | 1.892               | 1.702–3.148           | 0.017*  |                     |                      |         |
| lymph node metastasis (Presence/Absence) | 4.246               | 1.895–6.854           | 0.000*  |                     |                      |         |
| TNM stage (I+II/III+IV)               | 7.247               | 3.072–9.100           | 0.000*  |                     | 4.972                | 2.133–6.376 | 0.000* |
| CyclinD1 (High/Low)                   | 2.383               | 1.302–4.361           | 0.005*  |                     | 2.019                | 2.682–6.378 | 0.027* |
| p57Kip2 (High/Low)                    | 0.172               | 0.032–0.461           | 0.003*  |                     | 0.169                | 0.039–0.489 | 0.008* |

TNM, tumour-node-metastasis staging system; HR, hazard ratio; CI, confidence interval.*P < 0.05.
Immunohistochemical analysis

Sample slices for pathologic examination were reviewed to select the appropriate areas of GCA and its adjacent non-cancerous tissues. Tissue blocks that were matched for representative GCA and its adjacent non-cancerous tissues were collected from the tissue bank for the immunohistochemical assay of p57kip2 and cyclinD1. Tissue blocks to tissues from peripheral areas next to the tumor margin were standardized for all cases. Immunohistochemical analysis of the slices was performed by indirect immunoperoxidase staining [6]. The tissue specimens were incubated with diluted primary antibodies (1:250 dilution for p57kip2 and 1:400 dilution for cyclinD1), and control specimens were treated with PBS. Result analysis of slices for immunohistochemistry was performed by two independent pathologists, who had no prior knowledge on the data of the patients. The pathologists measured the immunohistochemical activities separately. Immunohistochemical staining was measured semi-quantitatively on the basis of the depth of staining, and were classified as follows: negative, when the average proportion of positive cells in 10 visual fields was < 25% under a 40× microscope; positive, when the average proportion of positive cells in 10 visual fields was > 25% under a 40× microscope.

Statistical analysis

Statistical analysis was performed using SPSS version 17.0 for Windows. Comparisons between the two groups were performed with t-test. Qualitative data (the expression of p57kip2 and cyclinD1) were analyzed using Chi-square test. Pearson analysis was used to calculate the correlation between clinicopathological features and the expression of p57kip2 and cyclinD1. The survival curve was calculated using the Kaplan-Meier method. Survival time was evaluated using the log-rank test. Univariate analysis and multivariate models were fit using a Cox proportional hazards regression model. A P-value < 0.05 was considered statistically significant.

CONCLUSIONS

In the present study, we also evaluated the relationship between the protein expression of p57kip2 and cyclinD1. Results revealed that the protein expression of p57kip2 was negatively correlated to the protein expression of cyclinD1 (P = 0.55). In GCA and its adjacent non-cancerous tissues, the expression of P57kip2 and cyclinD1 were significantly different; which implies that both proteins are involved in the malignant transformation of benign tissues, and both might exert a facilitation effect in this process. The relationship between these two proteins needs to be elucidated in future studies. Our findings indicate that both p57kip2 and cyclinD1 may become promising markers for predicting the prognosis of GCA, which is beneficial for the diagnosis and treatment of GCA.

Abbreviations

GCA: Gastric cardia adenocarcinoma; PCR: Polymerase chain reaction; RNA: Ribonucleic Acid; CDKI: Cyclin-dependent kinases inhibitors; RIPA: Radio Immunoprecipitation Assay; TBST: Tris-Buffered Saline and Tween 20; HRP: Horseradish Peroxidase; CTIP2: Chicken ovalbumin upstream promoter transcription factor-interacting protein 2; HES1: Hairy enhancer of split; ESCC: Esophageal squamous cell carcinoma; HPV: Human papilloma virus.

Authors’ contributions

RY and CXJ carried out the studies and drafted the manuscript. ZZW, ZPF and FSH participated in the design of the study and performed the statistical analysis. GQ, GSG and FXS revised it critically for important intellectual content. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS

We would like to thank all the participants in the studies.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.
REFERENCES

1. Guo W, Dong Z, Bai Y, Guo Y, Shen S, Kuang G, Xu J. Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China. Tumour Biol. 2015; 36:2845–54.

2. Olefson S, Moss SF. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric Cancer. 2015; 18:23–32.

3. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010; 182:1–17.

4. Thomas DD, Sommer AG, Balazs AB, Beerman I, Murphy GJ, Rossi D, Mostoslavsky G. Insulin-like growth factor 2 modulates murine hematopoietic stem cell maintenance through upregulation of p57. Exp Hematol. 2016; 44:422–433.e1.

5. Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, et al. CDK7, cyclin H, MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer. Clin Cancer Res. 2016; 22:5929–38.

6. Wang B, Gao ZQ, Yan X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 2005; 46:353–58.

7. Baziot Q, Paschos K, Skalska L, Kalchschmidt JS, Parker GA, Allday MJ. Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. PLoS Pathog. 2015; 11:e1005031.

8. Shin JY, Kim HS, Lee KS, Kim J, Park JB, Won MH, Chae SW, Choi YH, Choi KC, Park YE, Lee JY. Mutation and expression of the p27kip1 and p57kip2 genes in human gastric cancer. Exp Mol Med. 2000; 32:79–83.

9. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res. 2005; 11:4681–88.

10. Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K, Guo H. High Skp2/Low p57Kip2 Expression is Associated with Poor Prognosis in Human Breast Carcinoma. Breast Cancer (Auckl). 2015 (Suppl 1); 9:13–21.

11. Bozdoğan O, Atasoy P, Batislam E, Başar MM, Başar H. Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study. Tumori. 2008; 94:556–62.

12. Mishra S, Lin CL, Huang TH, Boumar H, Sun LZ. MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer. 2014; 13:212.

13. Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene. 2007; 26:1439–48.

14. Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, Miller LD, Tan PB, Yu Q. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One. 2009; 4:e5011.

15. Formari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008; 27:5651–61.

16. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2: “Kip”ing the cell under control. Mol Cancer Res. 2009; 7:1902–19.

17. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 2009; 100:1374–81.

18. Watanabe H, Tan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57Kip2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA. 1998; 95:1392–97.

19. Carey RG, Li B, DiCicco-Bloom E. Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity. J Neurosci. 2002; 22:1583–91.

20. Wierenga AT, Vellenga E, Schuringa JJ. Convergence of hypoxia and TGFβ pathways on cell cycle regulation in human hematopoietic stem/progenitor cells. PLoS One. 2014; 9:e93494.

21. Mairet-Coello G, Tury A, Van Buskirk E, Robinson K, Genestine M, DiCicco-Bloom E. p57(KIP2) regulates radial glia and intermediate precursor cell cycle dynamics and lower layer neurogenesis in developing cerebral cortex. Development. 2012; 139:475–87.

22. Topark-Ngarm A, Golonzhka O, Peterson VJ, Barrett B Jr, Martinez B, Cronin F, Filtz TM, Leid M. CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene. J Biol Chem. 2006; 281:32272–83.

23. Zalc A, Hayashi S, Auradé F, Bröhl D, Chang T, Mademetzoglou D, Mourikis P, Yao Z, Cao Y, Birchmeier C, Relaix F. Antagonistic regulation of p57Kip2 by Hes/Hey downstream of Notch signaling and muscle regulatory factors regulates skeletal muscle growth arrest. Development. 2014; 141:2780–90.

24. Dreyer JH, Hauck F, Barros MH, Niedobitek G. pRb and CyclinD1 Complement p16 as Immunohistochemical Surrogate Markers of HPV Infection in Head and Neck Cancer. Appl Immunohistochem Mol Morphol. 2017; 25:366–73.

FUNDING

Not applicable.

www.impactjournals.com/oncotarget
25. Li Z, Cui J, Yu Q, Wu X, Pan A, Li L. Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. Am J Transl Res. 2016; 8:142–53.

26. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998; 52:1–15.

27. Collecchi P, Passoni A, Rocchetta M, Gnesi E, Baldini E, Bevilacqua G. Cyclin-D1 expression in node-positive (N+) and node-negative (N-) infiltrating human mammary carcinomas. Int J Cancer. 1999; 84:139–44.

28. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 2002; 98:415–18.

29. Wang X, Zou S. The relationship of CyclinD1 and estrogen receptor expression in the process of proliferation and metastasis in breast neoplasm. J Tongji Med Univ. 2001; 21:231–32.

30. Tian F, Fan T, Zhang Y, Jiang Y, Zhang X. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2012; 44:847–55.

31. Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrandina G, Scambia G, Neri G. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res. 1996; 2:175–80.

32. Cattani P, Hohaus S, Bellacosa A, Genuardi M, Cavallo S, Rovella V, Almadori G, Cadoni G, Galli J, Maurizi M, Fadda G, Neri G. Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma. Clin Cancer Res. 1998; 4:2585–89.